small molecule

LUZU

LULICONAZOLE

Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyBAUSCH HEALTH US LLC

Drug detail

Brand nameLUZU
Active ingredientLULICONAZOLE
Strength1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalNovember 2013
Marketing statusRX

Listed patents

PatentExpiresType
8980931April 2034product
9012484September 2033substance, product
9453006September 2033substance
9199977September 2033substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LUZU patent cliff — loss of exclusivity April 2034 | CliffBio